Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

Topics: 

Citation
Lingvay I, et al. The Lancet Diabetes Endocrinol 2019.7(11):834-844.